Patents Assigned to ADARx Pharmaceutical, Inc.
-
Publication number: 20250115915Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.Type: ApplicationFiled: September 30, 2022Publication date: April 10, 2025Applicant: ADARx Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
-
Publication number: 20250073256Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.Type: ApplicationFiled: May 24, 2024Publication date: March 6, 2025Applicant: ADARx Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
-
Publication number: 20240401045Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of angiotensinogen (AGT). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT protein in a cell or animal.Type: ApplicationFiled: September 30, 2022Publication date: December 5, 2024Applicant: ADARx Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz
-
Patent number: 12042509Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.Type: GrantFiled: September 30, 2022Date of Patent: July 23, 2024Assignee: ADARx Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
-
Publication number: 20240191229Abstract: Aspects of the disclosure provide nucleic acids for reducing expression of a target RNA. In some aspects, the disclosure provides nucleic acid modifications and base-pairing configurations useful in the design of nucleic acids for RNA interference.Type: ApplicationFiled: April 13, 2022Publication date: June 13, 2024Applicant: ADARx Pharmaceuticals, Inc.Inventors: Zhen Li, Zhiqing (Joel) Zhou
-
Publication number: 20240083934Abstract: Provided herein are N-acetylgalactosamine (GalNAc)-derived compounds, modified oligonucleotides, and methods of modulating protein function and treating diseases, disorders, and symptoms in a subject.Type: ApplicationFiled: October 8, 2021Publication date: March 14, 2024Applicant: ADARx Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Mehdi Michel Djamel Numa, Bo Cheng, Chase Robert Olsson, Chandramouli Chiruta, Indrasena Reddy Kummetha
-
Publication number: 20240041913Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of angiotensinogen (AGT). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT protein in a cell or animal.Type: ApplicationFiled: March 31, 2023Publication date: February 8, 2024Applicant: ADARx Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Kimberly Fultz
-
Publication number: 20240043836Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB mRNA in a cell or animal. In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB protein in a cell or animal.Type: ApplicationFiled: November 23, 2022Publication date: February 8, 2024Applicant: ADARx Pharmaceuticals, IncInventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Sean Studer, Kimberly Fultz, Jean da Silva Correia
-
Publication number: 20230272391Abstract: Disclosed herein are compositions and methods for recruiting and using ADAR. In some aspects, compositions and methods for targeting ADAR activity to a desired region, sequence, or nucleotide are disclosed. In some aspects, compositions and methods for increasing the efficiency of directed ADAR editing are disclosed.Type: ApplicationFiled: July 30, 2021Publication date: August 31, 2023Applicant: ADARx Pharmaceutical, Inc.Inventors: Zhen Li, Rui Zhu, Jean da Silva Correia, Kimberly Fultz, Sean Studer, Sam Lear
-
Publication number: 20230158059Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.Type: ApplicationFiled: September 30, 2022Publication date: May 25, 2023Applicant: ADARx Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
